[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338621-105":59,"doc-detail-338621-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tasurgratinib-in-patients-with-cholangiocarcinoma-or-gastric-cancer-expansion-part-of-the-first-in-human-phase-i-study","Tasurgratinib in patients with cholangiocarcinoma or gastric cancer - Expansion part of the first-in-human phase I study","","Fibroblast growth factor receptor (FGFR) mutations occur in cancers such as gastric carcinoma and cholangiocarcinoma, motivating evaluation of Tasurgratinib, a selective FGFR1–3 inhibitor. Phase I dose escalation in 24 Japanese solid-tumor patients supported a once-daily recommended dose of 140 mg for the expansion phase (Part 2), a multicenter cohort of patients with FGFR-altered tumors. Part 2 enrolled 16 patients (6 cholangiocarcinoma, 10 gastric cancer) with safety, early efficacy, pharmacokinetics, and pharmacodynamic/pharmacogenomic markers assessed. Common adverse events included hyperphosphatemia and palmar-plantar erythrodysesthesia syndrome. Partial responses occurred in 83.3% of cholangiocarcinoma and 11.1% of gastric cancer patients; median progression-free survival was 8.26 and 3.25 months, respectively, and overall survival was 22.49 and 4.27 months. Results indicate tolerable safety and clinically meaningful activity in cholangiocarcinoma with FGFR2 rearrangements.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tasurgratinib-in-patients-with-cholangiocarcinoma-or-gastric-cancer-expansion-part-of-the-first-in-human-phase-i-study/338621/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tasurgratinib-in-patients-with-cholangiocarcinoma-or-gastric-cancer-expansion-part-of-the-first-in-human-phase-i-study/338621.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is Tasurgratinib and which targets does it inhibit?","Question",{"text":112,"@type":113},"Tasurgratinib is an oral inhibitor designed to selectively target the tyrosine kinase activities of FGFR1, FGFR2, and FGFR3.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the 140 mg once-daily dose selected for the expansion phase?",{"text":117,"@type":113},"Dose escalation data from the first-in-human phase I study supported selection of 140 mg once daily based on safety, pharmacokinetic, and pharmacodynamic findings.",{"name":119,"@type":110,"acceptedAnswer":120},"What efficacy and safety outcomes were observed in Part 2?",{"text":121,"@type":113},"In the expansion phase, partial responses were observed in cholangiocarcinoma and gastric cancer subgroups, with median progression-free survival and overall survival reported for each. Common treatment-emergent adverse events included hyperphosphatemia, palmar-plantar erythrodysesthesia syndrome, and paronychia.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338621,1790195662,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","DOI: 10. 1111/cas.16354  \nOR I G I NAL ART I C L E  \nTasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study  \nChigusa Morizane1 | Makoto Ueno2 | Tatsuya Ioka3 | Masahiro Tajika4 |  \nMasafumi Ikeda5  | Kensei Yamaguchi6 | Hiroki Hara7 | Hiroshi Yabusaki8 |  \nAtsushi Miyamoto9 | Satoru Iwasa1  | Manabu Muto10  | Tsutomu Takashima11 | Keiko Minashi12 | Yoshito Komatsu13  | Tomohiro Nishina14 | Takako Eguchi Nakajima15,16 | Atsuchi Takeno17 | Toshikazu Moriwaki18 | Masayuki Furukawa19 | Takatoshi Sahara20 | Hiroki Ikezawa20 | Maiko Nomoto20 | Shuya Takashima20 | Taisuke Uehara20 |  \nSetsuo Funasaka20 | Masakazu Yashiro11  | Junji Furuse2  \nCorrespondence  \nChigusa Morizane, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.  \nEmail: [cmorizan@ncc.go.jp](cmorizan@ncc.go.jp)  \nFunding information  \nEisai  \nAbstract  \nFibroblast growth factor receptors (FGFRs) are a highly conserved family of transmembrane receptor tyrosine kinases with multiple roles in the regulation of key cellular processes. Specific FGFR mutations have been observed in several types of cancers, including gastric carcinoma and cholangiocarcinoma. Dose escalation data of 24 Japanese patients with solid tumors treated with Tasurgratinib (previously known as E7090), a potent, selective FGFR1–3 inhibitor, was reported in a phase I, first-in-human, single-center study. Based on the safety, pharmacokinetic, and pharmacodynamic profiles observed in this study, the recommended dose of 140 mg once daily was selected for the expansion part (Part 2), a multicenter expansion of the dose-finding study restricted to patients with tumors harboring FGFR gene alterations. Safety and preliminary efficacy were assessed in Part 2. Pharmacodynamic pharmacogenomic markers (serum phosphate, FGF23, and 1,25-(OH)2-vitamin D, circulating tumor DNA) and pharmacokinetic profiles were also evaluated. A total of 16 patients were enrolled in Part 2, six with cholangiocarcinoma and 10 with gastric cancer. The most common treatment-emergent adverse events were hyperphosphatemia, palmarplantar erythrodysesthesia syndrome, and paronychia. Five partial responses (83 . 3%) in cholangiocarcinoma patients and one partial response (11 . 1%) in gastric cancer patients were observed; median progression-free survival was 8.26 months (95% confidence interval [CI] 3 . 84, not evaluable [NE]) and 3.25 months (95% CI 0.95, 4 . 86), and overall survival was 22.49 months (95% CI 6. 37, NE) and 4.27 months (95% CI 2. 23, 7.95), respectively, in the two groups. In conclusion, Tasurgratinib 140 mg has a  \nClinical trial registration: JapicCTI-142740; NCT02275910 . For affiliations refer to page 201.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2024 The Author(s) . Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.  \ntolerable safety profile with good clinical efficacy in patients with cholangiocarcinoma harboring FGFR2 gene rearrangements.  \nK E Y WO R D S  \ncholangiocarcinoma, E7090, FGFR2, gastric cancer, Tasurgratinib  \n1 | INTRODUCTION  \nFibroblast growth factor receptors (FGFRs), a family of four highly conserved transmembrane receptor tyrosine kinases (FGFR1–4) and one receptor that can bind fibroblast growth factor (FGF) ligands,1 play important roles in a variety of biological functions, including cellular proliferation, differentiation, migration, and angiogenesis.2 Genomic alterations in FGFRs, including gene amplifications and chromosomal translocations that trigger pathway activations,3,4 have been identified in multiple types of solid tumors. 5,6 FGFR2 dysregulation has been reported in gastric carcinomas7,8 and cholan","cbCaiaGvRYAZRsq4","https://ap.wps.com/l/cbCaiaGvRYAZRsq4","pdf",616043,12,"English","# Introduction\n## FGFR biology and relevance to solid tumors\n## Epidemiology and FGFR2 alterations in gastric cancer and cholangiocarcinoma\n## Rationale for selective FGFR inhibition and prior therapies\n## Tasurgratinib mechanism and preclinical activity","[{\"question\":\"What is Tasurgratinib and which targets does it inhibit?\",\"answer\":\"Tasurgratinib is an oral inhibitor designed to selectively target the tyrosine kinase activities of FGFR1, FGFR2, and FGFR3.\"},{\"question\":\"How was the 140 mg once-daily dose selected for the expansion phase?\",\"answer\":\"Dose escalation data from the first-in-human phase I study supported selection of 140 mg once daily based on safety, pharmacokinetic, and pharmacodynamic findings.\"},{\"question\":\"What efficacy and safety outcomes were observed in Part 2?\",\"answer\":\"In the expansion phase, partial responses were observed in cholangiocarcinoma and gastric cancer subgroups, with median progression-free survival and overall survival reported for each. Common treatment-emergent adverse events included hyperphosphatemia, palmar-plantar erythrodysesthesia syndrome, and paronychia.\"}]","Tasurgratinib in patients with cholangiocarcinoma or gastric cancer - Expansion part of the first-in-human phase I study | PDF",1790024637,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6263c5ff639dbde1844d1ca595d85bce.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00f32cb23e7cb59f292bed43c619a806.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f5f4bb39943dc592f412baafdc96161.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06f97a7f851a952b52296d09a5e7042c.webp",980,1287]